SURF — Surface Oncology Share Price
0.000.00%
Last trade - 00:00HealthcareAdventurousSmall Cap
- $65.08m
- $8.82m
- $30.00m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.74 | ||
| Price to Tang. Book | 0.74 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -72.28% | ||
| Return on Equity | -80.36% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 59.42 | 15.36 | 126.16 | 2.69 | 30 | 3.75 | n/a | 18.52% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Surface Oncology, Inc. is a clinical-stage, immuno-oncology company, which is focused on developing immunotherapies that target the tumor microenvironment. The Company is developing multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable an immunologic response and enhance outcomes for patients with cancer. The Company’s pipeline includes two wholly owned clinical-stage programs targeting IL-27 (SRF388) and SRF114 a preclinical program focused on depleting tumor regulatory T cells through targeting CCR8. In addition, the Company has two partnerships with pharmaceutical companies, including a collaboration with Novartis targeting CD73 (NZV930; Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (GSK4381562). The Company’s novel cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies.
Directors
- Denice Torres CHM (61)
- Robert Ross PRE (47)
- Jessica Fees CFO (49)
- Lisa Mcgrath CHO
- Vito Palombella CSO (59)
- Wendy Dwyer OTH (47)
- Alison O'Neill OTH
- Henry Rath OTH
- Liisa Nogelo SEC (50)
- J. Jeffrey Goater DRC (45)
- Benjamin Hickey DRC (46)
- David Grayzel IND (53)
- Ramy Ibrahim IND (46)
- Cameron Mcdonough IND (50)
- Armen Shanafelt IND (61)
- Elliott Sigal IND (69)
- Laurie Stelzer IND (53)
- Last Annual
- December 31st, 2022
- Last Interim
- March 31st, 2023
- Incorporated
- April 29th, 2014
- Public Since
- April 19th, 2018
- No. of Shareholders
- 7
- No. of Employees
- 60
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 60,716,873
- Address
- 50 Hampshire Street, 8Th Floor, CAMBRIDGE, 02139
- Web
- https://www.surfaceoncology.com/
- Phone
- +1 6177144096
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for SURF
Q3 2023 Surface Oncology Inc Earnings Release
Similar to SURF
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Aceragen
NASDAQ Capital Market
Acer Therapeutics
NASDAQ Capital Market
FAQ
What is the Surface Oncology share price?
As of Today at 07:22 UTC, shares in Surface Oncology are trading at $0.93. This share price information is delayed by 15 minutes.
How has the Surface Oncology share price performed this year?
Shares in Surface Oncology last closed at $0.93 and the price had moved by -46.98% over the past 365 days. In terms of relative price strength the Surface Oncology share price has underperformed the S&P500 Index by -54.49% over the past year.
What are the analyst and broker recommendations for Surface Oncology?
The overall consensus recommendation for Surface Oncology is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Surface Oncology dividend yield?
Surface Oncology does not currently pay a dividend.
Does Surface Oncology pay a dividend?
Surface Oncology does not currently pay a dividend.
When does Surface Oncology next pay dividends?
Surface Oncology does not currently pay a dividend.
How do I buy Surface Oncology shares?
To buy shares in Surface Oncology you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Surface Oncology?
As of the previous close price of $0.93, shares in Surface Oncology had a market capitalisation of $55.86m.
Where are Surface Oncology shares listed?
Here are the trading details for Surface Oncology:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: SURF
What kind of share is Surface Oncology?
Based on an overall assessment of its quality, value and momentum Surface Oncology is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Surface Oncology share price forecast for 2023?
The analyst consensus target price for shares in Surface Oncology is $2.40. That is 158.7% above the last closing price of $0.93.
Analysts covering Surface Oncology currently have a consensus Earnings Per Share (EPS) forecast of -$1.29 for the next financial year.
Find out moreWhat is the trend in the Surface Oncology share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Surface Oncology. Over the past six months, its share price has underperformed the S&P500 Index by -10.12%.
As of the last closing price of $0.93, shares in Surface Oncology were trading +10.23% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Surface Oncology PE Ratio?
The Surface Oncology PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.93.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Surface Oncology?
Surface Oncology's management team is headed by:
- Denice Torres - CHM
- Robert Ross - PRE
- Jessica Fees - CFO
- Lisa Mcgrath - CHO
- Vito Palombella - CSO
- Wendy Dwyer - OTH
- Alison O'Neill - OTH
- Henry Rath - OTH
- Liisa Nogelo - SEC
- J. Jeffrey Goater - DRC
- Benjamin Hickey - DRC
- David Grayzel - IND
- Ramy Ibrahim - IND
- Cameron Mcdonough - IND
- Armen Shanafelt - IND
- Elliott Sigal - IND
- Laurie Stelzer - IND